Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
Please note that the ANZCTR website will be unavailable from 9am until 12:30pm (AEDT) on Tuesday 17th November for website maintenance.
Please be sure to log out of the system in order to avoid any loss of data. Thank you and apologies for any inconvenience caused.
A database of clinical trials and their results from Australia, New Zealand, and other countries.
account_circle
Log in
to register or update your trial
search
Search for trials
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT06879041
Registration number
NCT06879041
Ethics application status
Date submitted
11/03/2025
Date registered
17/03/2025
Date last updated
16/10/2026
Titles & IDs
Public title
A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer
Query!
Scientific title
A Phase I, First-in-human, Dose Escalation Study Of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer
Query!
Additional trial identifiers [1]
0
0
D7580C00001
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Related trial records
Query!
Health condition
Health condition(s) studied:
Metastatic Castration-Resistant Prostate Cancer
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Prostate
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of the intervention or exposure
Treatment: Drugs - AZD2287
Treatment: Drugs - AZD2275
Treatment: Drugs - AZD2284
Experimental: Part A: Cohort A1: AZD2287 (Hot only) - Participants will receive AZD2287. If eligible for treatment, will receive dose level (DL)1 of AZD2284.
Experimental: Part A: Cohort A2: AZD2275 + AZD2287 (Cold +Hot) - Participants will receive DL1 of AZD2275 followed by AZD2287. If eligible for treatment, will receive DL1 of AZD2284.
Experimental: Part A: Cohort A3: AZD2275 + AZD2287 (Cold +Hot) - Participants will receive DL2 of AZD2275 followed by AZD2287. If eligible for treatment, will receive DL1 of AZD2284.
Experimental: Part B (Actinium-225 Dose Escalation): DL1: AZD2284 - Participants will receive AZD2287 (± AZD2275 as determined in Part A). If eligible for treatment, will receive DL1 of AZD2284.
Experimental: Part B (Actinium-225 Dose Escalation): DL2: AZD2284 - Participants will receive AZD2287 (± AZD2275 as determined in Part A). If eligible for treatment, will receive DL2 of AZD2284.
Experimental: Part B (Actinium-225 Dose Escalation): DL3: AZD2284 - Participants will receive AZD2287 (± AZD2275 as determined in Part A). If eligible for treatment, will receive DL3 of AZD2284.
Experimental: Part B (Actinium-225 Dose Escalation): DL4: AZD2284 - Participants will receive AZD2287 (± AZD2275 as determined in Part A). If eligible for treatment, will receive DL4 of AZD2284.
Experimental: Part B: Cohort E1 - Participants will receive dose of AZD2284 determined by the earlier results. Expansion cohort may be opened to further characterize the safety and efficacy of the dose level.
Experimental: Part B: Cohort E2 - Participants will receive dose of AZD2284 determined by the earlier results. Expansion cohort may be opened to further characterize the safety and efficacy of the dose level.
Treatment: Drugs: AZD2287
Participants will receive AZD2287
Treatment: Drugs: AZD2275
Participants will receive AZD2275
Treatment: Drugs: AZD2284
Participants will receive AZD2284
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Description of the comparator or control
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Number of participants with adverse event (AEs)
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Part A: Up to Day 28; Part B: Up to 5 years
Query!
Primary outcome [2]
0
0
Number of participants with Dose Limiting Toxicities (DLTs)
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
Part B: Up to 84 days of receiving AZD2284
Query!
Primary outcome [3]
0
0
Estimates of residence time
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
Part A: Up to 8 days after a dose of AZD2287
Query!
Primary outcome [4]
0
0
Absorbed radiation doses for AZD2287 and AZD2284
Query!
Assessment method [4]
0
0
Query!
Timepoint [4]
0
0
Part A: Up to 8 days after a dose of AZD2287; Part B: Up to 7 days after a dose of AZD2287
Query!
Primary outcome [5]
0
0
Compare organ uptake of AZD2287 with and without pre-dose administration of AZD2275
Query!
Assessment method [5]
0
0
Query!
Timepoint [5]
0
0
Part A: Up to 8 days after a dose of AZD2287; Part B: Up to 7 days after a dose of AZD2287
Query!
Primary outcome [6]
0
0
Tumor uptake of AZD2287 in selected regions of interest on SPECT/CT and/or planar images
Query!
Assessment method [6]
0
0
Query!
Timepoint [6]
0
0
Part A: Up to 8 days after a dose of AZD2287; Part B: Up to 7 days after a dose of AZD2287
Query!
Secondary outcome [1]
0
0
Overall Response Rate (ORR)
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Up to 12 months after the last dose of AZD2284
Query!
Secondary outcome [2]
0
0
Proportion of participants with Prostate-Specific Antigen (PSA) 50
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
Up to 12 months after the last dose of AZD2284
Query!
Secondary outcome [3]
0
0
Proportion of participants with PSA90
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
Up to 12 months after the last dose of AZD2284
Query!
Secondary outcome [4]
0
0
Time to PSA50 response
Query!
Assessment method [4]
0
0
Query!
Timepoint [4]
0
0
Up to 12 months after the last dose of AZD2284
Query!
Secondary outcome [5]
0
0
Duration of Response (DoR)
Query!
Assessment method [5]
0
0
Query!
Timepoint [5]
0
0
Up to 12 months after the last dose of AZD2284
Query!
Secondary outcome [6]
0
0
Radiographic Progression Free Survival (rPFS)
Query!
Assessment method [6]
0
0
Query!
Timepoint [6]
0
0
Up to 12 months after the last dose of AZD2284
Query!
Secondary outcome [7]
0
0
Overall Survival (OS)
Query!
Assessment method [7]
0
0
Query!
Timepoint [7]
0
0
Part A: Up to Day 28; Part B: Up to 5 years
Query!
Secondary outcome [8]
0
0
Pharmacokinetic Clearance
Query!
Assessment method [8]
0
0
Query!
Timepoint [8]
0
0
Part A: Up to Day 28; Part B: Up to 84 days
Query!
Secondary outcome [9]
0
0
Area under concentration-curve from time 0 to the last quantifiable concentration (AUClast)
Query!
Assessment method [9]
0
0
Query!
Timepoint [9]
0
0
Part A: Up to Day 28; Part B: Up to 84 days
Query!
Secondary outcome [10]
0
0
Maximum observed drug concentration (Cmax)
Query!
Assessment method [10]
0
0
Query!
Timepoint [10]
0
0
Part A: Up to Day 28; Part B: Up to 84 days
Query!
Secondary outcome [11]
0
0
Half-life (t1/2)
Query!
Assessment method [11]
0
0
Query!
Timepoint [11]
0
0
Part A: Up to Day 28; Part B: Up to 84 days
Query!
Secondary outcome [12]
0
0
Changes in plasma concentrations of AZD2287 and AZD2284 following AZD2275 pre-administration compared to AZD2287 and AZD2284 alone
Query!
Assessment method [12]
0
0
Query!
Timepoint [12]
0
0
Part A: Up to Day 28; Part B: Up to 84 days
Query!
Secondary outcome [13]
0
0
Number of participants with positive antidrug antibodies (ADAs)
Query!
Assessment method [13]
0
0
Query!
Timepoint [13]
0
0
Part A: Up to Day 28; Part B: Approximately 28 days after End of Treatment (EOT) visit
Query!
Eligibility
Key inclusion criteria
* eria:
* • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
* • Histologically confirmed diagnosis of adenocarcinoma of the prostate without strong clinical suspicion of majority neuroendocrine differentiation.
* • Must have had prior bilateral orchiectomy and/or ongoing androgen-deprivation therapy and a castrate level of serum/plasma testosterone (< 50 ng/dL or < 1.7 nmol/L).
* • At least one metastatic lesion present on baseline Computed Tomography (CT), Magnetic Resonance Imaging (MRI), or bone scan obtained = 28 days prior to the first dose of Investigational Medicinal Product (IMP). Participants may have non-measurable lesions including bone only metastases.
* • Adequate organ function
* • Part A only: Metastatic prostate cancer considered to be stable or progressing metastatic castration resistant prostate cancer (mCRPC).
* • Part B only: Progressing mCRPC defined as meeting at least one of following documented criteria -
* a)Serum/plasma PSA progression
* b)Soft-tissue progression
* c)Progression of bone disease
* • Part B Dose Escalation: Previously treated with at least 2 prior lines of systemic anti-cancer therapy for mCRPC. Prior lines must include:
* a)At least 1 androgen receptor pathway inhibitor (ARPI)
* b)A poly (adp-ribose) polymerase (PARP) inhibitor for participants with known BRCA mutation
* c)A checkpoint inhibitor for participants with known microsatellite instability-high (MSI-H), deficient mismatch pair (dMMR), or tumor mutational burden (TMB) = 10 mut/Mb
* • Part B Dose Expansion: Previously treated with at least 1 prior line of systemic anti-cancer therapy for mCRPC. Prior lines must include:
* (a)At least 1 ARPI
* (b)A PARP inhibitor for participants with known BRCA mutation per local practice, unless ineligible per Investigator decision.
* (c)A checkpoint inhibitor for participants with known MSI-H, dMMR, or TMB = 10 mut/Mb.
* (d)No previous cytotoxic chemotherapy for CRPC. Taxanes for metastatic hormone sensitive prostate cancer (mHSPC) is acceptable if the last cycle Day 1 was > 12 months before first study treatment.
* (e)Previous treatment with prostate specific membrane antigen radioligand therapy (PSMA-RLT) or Radium-223 is allowed but not required. Participants who have had prior radiation therapy, including therapeutic radiopharmaceuticals, external bean radiation therapy (EBRT), and/or brachytherapy are eligible, subject to satisfying all other inclusion/exclusion criteria. Therapeutic radiopharmaceuticals will be considered a prior line of systemic therapy.
* Main
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Males
Query!
Healthy volunteers
No
Query!
Key exclusion criteria
* • Treatment with any radiopharmaceutical within 6 weeks of the first dose of Investigational Medicinal Product (IMP).
* • Radiation therapy (RT) or external beam radiation therapy (EBRT) within 28 days prior to the first dose and all RT-related events have not recovered to Grade = 1.
* • Administration of any systemic cytotoxic or investigational therapy = 28 days of the first dose of IMP or 5 half-lives, whichever is shorter.
* • All prior treatment-related adverse events must have resolved to Grade = 1.
* • Concurrent severe and/or uncontrolled illness not related to cancer and/or social situation that would limit compliance with study requirements.
* • Known or suspected allergies or contraindications to any of the investigational drugs or any component of the investigational drug formulation.
* • Clinically relevant proteinuria
* • Diffuse and intense osseous radiotracer uptake on bone scintigraphy or PSMA imaging characteristic of a superscan.
* • Chronic corticosteroid use greater than 10 mg prednisone equivalent daily.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Other
Query!
Other design features
Query!
Phase
Phase 1
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
10/03/2025
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
16/04/2029
Query!
Actual
Query!
Sample size
Target
136
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
Research Site - East Melbourne
Query!
Recruitment postcode(s) [1]
0
0
3002 - East Melbourne
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Florida
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Illinois
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Louisiana
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Massachusetts
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Minnesota
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Nebraska
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
New York
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Ohio
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Oregon
Query!
Country [11]
0
0
South Africa
Query!
State/province [11]
0
0
CapeTown
Query!
Country [12]
0
0
South Africa
Query!
State/province [12]
0
0
Durban
Query!
Country [13]
0
0
South Africa
Query!
State/province [13]
0
0
Pretoria
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
AstraZeneca
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/industry
Query!
Name [1]
0
0
Parexel
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The main purpose of the study is to assess the safety and tolerability of AZD2284, AZD2287, and AZD2275.
Query!
Trial website
https://clinicaltrials.gov/study/NCT06879041
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
AstraZeneca Clinical Study Information Center
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
1-877-240-9479
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
Query!
What data in particular will be shared?
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure."Yes",indicatesthat AZ are accepting requests for IPD, but this does not mean all requests will be approved.
Query!
When will data be available (start and end dates)?
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment athttps://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Query!
Available to whom?
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Query!
Available for what types of analyses?
Query!
How or where can data be obtained?
IPD available at link: https://vivli.org/
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT06879041
Download to PDF